Endlyz is supported by leading investors, including SV Health Investors’ Dementia Discovery Fund, Oxford Science Enterprises, ...

The randomized, double-blind, placebo-controlled trial aims to assess the safety, tolerability, and efficacy of intranasal foralumab in patients with na-SPMS, a form of multiple sclerosis (MS) ...

Physician-scientists at Memorial Sloan Kettering Cancer Center (MSK) recently published two papers that advance the science ...

EpimAb Biotherapeutics, a clinical stage biotechnology company specializing in the development of bispecific antibodies and T ...

Interleukins are cytokines produced and secreted mainly by CD3+ and CD4+ T lymphocytes. Interleukins promote development and differentiation of natural killer cells, T and B lymphocytes and ...

Chardan Capital issued their FY2025 earnings per share (EPS) estimates for shares of iBio in a research note issued to investors on Monday, March 24th. Chardan Capital analyst K. Nakae forecasts that ...

Portage Biotech unveils new preclinical data on PORT-7, showing strong antitumor effects in mesothelioma and advancing plans for clinical trials.

PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) has announced that new research on its clinical asset, CT-95, ...

BioAtla is laying off 30% of staff as the biotech searches for partners for some of its conditionally active biologic (CAB) ...

Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of innovative therapeutics, presented new preclinical data ...

Context Therapeutics Inc.’s CNTX share price has dipped by 11.07%, which has investors questioning if this is right time to buy.

Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ETCompany ParticipantsBruce Mackle - LifeSci Advisors, ...